Pacer Advisors Inc. Has $11.13 Million Stock Position in Danaher Co. (NYSE:DHR)

Pacer Advisors Inc. reduced its position in shares of Danaher Co. (NYSE:DHRFree Report) by 31.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,109 shares of the conglomerate’s stock after selling 22,181 shares during the period. Pacer Advisors Inc.’s holdings in Danaher were worth $11,130,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of DHR. DHJJ Financial Advisors Ltd. acquired a new position in shares of Danaher during the third quarter worth $25,000. BKM Wealth Management LLC bought a new stake in shares of Danaher in the fourth quarter worth $27,000. OFI Invest Asset Management bought a new stake in shares of Danaher in the third quarter worth $30,000. First Capital Advisors Group LLC. bought a new stake in shares of Danaher in the second quarter worth $32,000. Finally, BOK Financial Private Wealth Inc. bought a new stake in shares of Danaher in the third quarter worth $34,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Up 0.3 %

Danaher stock opened at $248.46 on Wednesday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The firm has a 50 day moving average price of $246.25 and a 200-day moving average price of $230.40. The company has a market capitalization of $183.79 billion, a P/E ratio of 38.88, a P/E/G ratio of 3.87 and a beta of 0.84. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHRGet Free Report) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same period in the prior year, the firm earned $2.87 EPS. The company’s revenue was down 10.2% compared to the same quarter last year. As a group, equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s payout ratio is presently 15.02%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Wolfe Research initiated coverage on shares of Danaher in a research report on Wednesday, December 13th. They set a “peer perform” rating on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Royal Bank of Canada increased their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Raymond James increased their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, HSBC began coverage on shares of Danaher in a report on Monday, December 18th. They issued a “hold” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $266.00.

Get Our Latest Report on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.